Endocan, ET-1, and ETAR Expression Profiles in Unicystic Ameloblastoma, Multicystic Ameloblastoma, and Ameloblastic Carcinoma
Journal Title: Middle East Journal of Cancer - Year 2019, Vol 10, Issue 3
Abstract
Background: Odontogenic lesions range from simple cysts to benign tumors and carcinomas. Unicystic ameloblastoma is a monocystic lesion and a less aggressive tumor compared to multicystic ameloblastoma. Ameloblastic carcinoma is the malignant variant of the multicystic ameloblastoma and may arise de novo or from malignant transformation of a long-standing multicystic ameloblastoma. Methods:We collected 54 tissue samples obtained from patients from 2000-2017 that were stored in the archives section of the Pathology Department of Taleghani Educational Hospital, Tehran, Iran. The specimens were processed for immunohistochemistry analysis. Immunostaining of the markers was assessed via quantitative methods. Statistical analysis was performed using one-way ANOVA and the chisquare test. Results: One-way ANOVA analysis and the chi-square test did not reveal any statistically significant differences between the expression levels of endocan, ET-1, and ETAR and lesion type. A positive correlation existed between ET-1 and ETAR expression levels in unicystic ameloblastoma and multicystic ameloblastoma (Pearson’s r = 0.506, P<0.002), and between ET-1 and ETAR expression levels in unicystic ameloblastoma and ameloblastic carcinoma (Pearson’s r = 0.376, P<0.024). Conclusion: This study revealed a positive correlation between the histological degree of lesion and endocan, ET-1, and ETAR expression levels. Hence, it might suggest that multicystic ameloblastoma develops from unicystic ameloblastoma. Over time, multicystic ameloblastoma may undergo a malignant transformation to ameloblastic carcinoma. Possibly, a simple cystic neoplasm can progress to a cystic lesion with invasion to the connective tissue wall and a gradual development into a true neoplasm (multicystic ameloblastoma), with potential for malignant transformation (ameloblastic carcinoma). Endocan, ET-1, and ETAR can be used as prognostic biomarkers for different variants of multicystic ameloblastoma and possible new targets for cancer therapy.
Authors and Affiliations
Soussan Irani, Zhaleh Mohsenifar
Keywords
Related Articles
- EP ID EP638896
- DOI 10.30476/mejc.2019.78562.
- Views 86
- Downloads 0
Evaluation of an Immunomodulator Drug as a Radioprotectant on Human Peripheral Blood Lymphocytes In Vitro
Background: IMOD™, a selenium enriched extract of the plants Tanacetum vulgare, Urtica dioica, and Rosa canina, has an excellent effect on oxidative stress. In this study, we investigated the radioprotective effects of t...
Salivary Lactate Dehydrogenase (LDH) as a Marker for Radiation-induced Mucositis in Head and Neck Cancers: A Preliminary Study
Background: In this study, we sought to understand the usefulness of salivary lactate dehydrogenase as a predictive marker for the development of radiation-induced mucositis. Methods: This was a prospective study with he...
Evaluation of a Number of Blood Biochemical Markers after Radioiodine Therapy in Papillary Thyroid Cancer Patients
Background: This study aimed to assess several biochemical and oxidative stress parameters before and after radioiodine therapy in patients with well-differentiated thyroid cancer who consumed a low iodine diet and withd...
Pain Coping Strategies and Their Relationship with Unpleasant Emotions (Anxiety, Stress, and Depression) and Religious Coping in Cancer Patients
Background: Coping strategies affect patients’ perceptions of pain severity, their ability to tolerate pain, duration of daily activities, and emotions. This study aims to determine the relationship between pain coping a...
Struma Ovarii Associated with Pseudo-Meigs’ Syndrome: A Rare Presentation of an Infrequent Tumor
Struma ovarii is an uncommon highly specialized ovarian teratoma that accounts for less than 5% of mature teratomas. It is composed predominantly of mature thyroid tissue. Thyroid tissue is observed in 5%-15% of teratoma...